medigraphic.com
ISSN 0035-0052 (Print)

2021, Number 6

Next >>

Rev Mex Pediatr 2021; 88 (6)

COVID-19: from the health crisis to the employment crisis

Calva RRG

Language: Spanish
References: 7
Page: 221-222
PDF size: 128.98 Kb.





REFERENCES

  1. Anichini G, Terrosi C, Gandolfo C, Gori Savellini G, Fabrizi S, Miceli GB et al. SARS-CoV-2 Antibody response in persons with past natural infection. N Engl J Med. 2021; 385(1): 90-92. doi: 10.1056/NEJMc2103825.

  2. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021; 371(6529): eabf4063. doi: 10.1126/science.abf4063.

  3. Pulliam JRC, Van Schalkwyk C, Govender N, Von Gottberg A, Cohen C, Groome MJ et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa. 2021. Available in: https://doi.org/10.1101/2021.11.11.21266068; (2021)

  4. Escandón K, Rasmussen AL, Bogoch II, Murray EJ, Escandón K, Popescu SV et al. COVID-19 false dichotomies and a comprehensive review of the evidence regarding public health, COVID-19 symptomatology, SARS-CoV-2 transmission, mask wearing, and reinfection. BMC Infect Dis. 2021; 21(1): 710. Available in: https://doi.org/10.1186/s12879-021-06357-4

  5. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020; 26(8): 1200-1204. Available in: https://doi.org/10.1038/s41591-020-0965-6 (2021)

  6. Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021; 21(10): 626-636. doi: 10.1038/s41577-021-00592-1.

  7. Abdool Karim SS, de Oliveira T. New SARS-CoV-2 Variants-clinical, public health, and vaccine implications. N Engl J Med. 2021; 384(19): 1866-1868. doi: 10.1056/NEJMc2100362.




2020     |     www.medigraphic.com